ENTBF
Price
$0.09
Change
-$0.02 (-18.18%)
Updated
Jun 6 closing price
Capitalization
1.12M
XTLB
Price
$1.12
Change
-$0.08 (-6.67%)
Updated
Jun 13 closing price
Capitalization
10.11M
Interact to see
Advertisement

ENTBF vs XTLB

Header iconENTBF vs XTLB Comparison
Open Charts ENTBF vs XTLBBanner chart's image
ENTHEON BIOMEDICAL
Price$0.09
Change-$0.02 (-18.18%)
Volume$766
Capitalization1.12M
XTL Biopharmaceuticals
Price$1.12
Change-$0.08 (-6.67%)
Volume$66.4K
Capitalization10.11M
ENTBF vs XTLB Comparison Chart
Loading...
View a ticker or compare two or three
VS
ENTBF vs. XTLB commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTBF is a Hold and XTLB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (ENTBF: $0.09 vs. XTLB: $1.12)
Brand notoriety: ENTBF and XTLB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTBF: 46% vs. XTLB: 610%
Market capitalization -- ENTBF: $1.12M vs. XTLB: $10.11M
ENTBF [@Biotechnology] is valued at $1.12M. XTLB’s [@Biotechnology] market capitalization is $10.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTBF’s FA Score shows that 0 FA rating(s) are green whileXTLB’s FA Score has 0 green FA rating(s).

  • ENTBF’s FA Score: 0 green, 5 red.
  • XTLB’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTBF is a better buy in the long-term than XTLB.

Price Growth

ENTBF (@Biotechnology) experienced а 0.00% price change this week, while XTLB (@Biotechnology) price change was +1.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
XTLB($10.1M) has a higher market cap than ENTBF($1.12M). ENTBF YTD gains are higher at: -34.188 vs. XTLB (-44.713). ENTBF has more cash in the bank: 525K vs. XTLB (133K).
ENTBFXTLBENTBF / XTLB
Capitalization1.12M10.1M11%
EBITDA-403.94KN/A-
Gain YTD-34.188-44.71376%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash525K133K395%
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
XTLB: Fundamental Ratings
XTLB
OUTLOOK RATING
1..100
1
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
84
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IBDT25.22-0.03
-0.12%
iShares iBonds Dec 2028 Term Corp ETF
RAFE36.85-0.49
-1.31%
PIMCO RAFI ESG US ETF
JRS7.75-0.13
-1.65%
Nuveen Real Estate Income Fund
ECH31.83-0.68
-2.09%
iShares MSCI Chile ETF
BITW62.36-2.14
-3.32%
Bitwise 10 Crypto Index Fund

ENTBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTBF has been loosely correlated with SER. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTBF jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTBF
1D Price
Change %
ENTBF100%
N/A
SER - ENTBF
35%
Loosely correlated
+1.27%
IMRX - ENTBF
31%
Poorly correlated
-3.06%
XTLB - ENTBF
29%
Poorly correlated
-6.67%
GERN - ENTBF
27%
Poorly correlated
-3.21%
AIMI - ENTBF
23%
Poorly correlated
N/A
More

XTLB and

Correlation & Price change

A.I.dvisor indicates that over the last year, XTLB has been closely correlated with LABFF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if XTLB jumps, then LABFF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTLB
1D Price
Change %
XTLB100%
-6.67%
LABFF - XTLB
70%
Closely correlated
N/A
SER - XTLB
59%
Loosely correlated
+1.27%
ENTBF - XTLB
29%
Poorly correlated
N/A
SOLTF - XTLB
26%
Poorly correlated
N/A
TSHA - XTLB
26%
Poorly correlated
-4.15%
More